FDA Approved Drugs by Medical Condition

Search by medical condition for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Select the letter below that corresponds to the first letter of the medical condition you are searching for and all approved drugs classified under that category will be listed below.

Leukemia

Besponsa (inotuzumab ozogamicin) (by Pfizer), Approved August 2017
For the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia

Blincyto (blinatumomab) (by Amgen), Approved December 2014
For the treatment of Philadelphia chromosome-negative relapsed /refractory B cell precursor acute lymphoblastic leukemia

Bosulif (bosutinib) (by Pfizer), Approved September 2012
For the treatment of Ph+ chronic myelogenous leukemia

Campath (by Berlex Laboratories), Approved May 2001
Injectable treatment of B-cell chronic lymphocytic leukemia

Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection) (by Orphan Medical), Approved October 1996
Treatment of meningeal leukemia or lymphocytic lymphoma

Erwinaze (asparaginase Erwinia chrysanthemi) (by Eusa Pharma), Approved November of 2011
For the treatment of acute lymphoblastic leukemia

Imbruvica (ibrutinib) (by Pharmacyclics), Approved February 2014
For the treatment of chronic lymphocytic leukemia and Waldenstrom macroglobulinemia

Imbruvica (ibrutinib) (by Pharmacyclics), Approved November of 2013
For the treatment of mantle cell lymphoma

Kymriah (tisagenlecleucel) (by Novartis), Approved August 2017
For the treatment of refractory B-cell precursor acute lymphoblastic leukemia

Marqibo (vinCRIStine sulfate LIPOSOME injection) (by Talon Therapeutics), Approved August 2012
For the treatment of Ph- acute lymphoblastic leukemia

Leukemia (Pediatric)

Kymriah (tisagenlecleucel) (by Novartis), Approved August 2017
For the treatment of refractory B-cell precursor acute lymphoblastic leukemia

Liver Cancer

Feridex I.V. (by Advanced Magnetics), Approved February 1996
Contrast agent for magnetic resonance imaging of liver lesions

Liver Disease

Defitelio (defibrotide sodium) (by Jazz Pharmaceuticals), Approved March 2016
For the treatment of hepatic veno-occlusive disease with renal or pulmonary dysfunction following HSCT

Ocaliva (obeticholic acid) (by Intercept Pharmaceuticals), Approved May 2016
For the treatment of primary biliary cholangitis

Liver Disorders

Cholbam (cholic acid) (by Asklepion Pharmaceuticals), Approved March 2015
For the treatment of bile acid synthesis and peroxisomal disorders

Low Blood Pressure (Hypotension)

ProAmatine (midodrine) (by Roberts Pharmaceutical), Approved September 1996
Treatment for hypotension

Low Testosterone

Vogelxo (testosterone) gel (by Upsher-Smith), Approved June 2014
For males with a deficiency or absence of endogenous testosterone

Lung Cancer

Abraxane (paclitaxel protein-bound particles for injectable suspension) (by Celgene), Approved October 2012
For the treatment of non-small cell lung cancer

Alecensa (alectinib) (by Roche), Approved December 2015
For the treatment of ALK-positive, metastatic non-small cell lung cancer

Alunbrig (brigatinib) (by Ariad Pharmaceuticals), Approved April 2017
For the treatment of advanced ALK-positive metastatic non-small cell lung cancer

Gemzar (gemcitabine HCL) (by Eli Lilly), Approved August 1998
Treatment for Lung Cancer

Hycamtin (topotecan hydrochloride) (by GlaxoSmithKline), Approved October 2007
For the treatment of small cell lung cancer

Iressa (gefitinib) (by AstraZeneca), Approved May 2003
For the second-line treatment of non-small-cell lung cancer

Keytruda (pembrolizumab) (by Merck), Approved October 2015
For the treatment of PD-L1 positive advanced non-small cell lung cancer

Opdivo (nivolumab) (by Bristol-Myers Squibb), Approved March 2015
For the treatment of metastatic squamous non-small cell lung cancer

Photofrin (by QLT), Approved January 1998
Treatment for early-stage, microinvasive endobronchial non-small cell lung cancer

Portrazza (necitumumab) (by Eli Lilly), Approved November 2015
For the treatment of metastatic squamous non-small cell lung cancer

Tarceva (erlotinib, OSI 774) (by Genentech, OSI Pharmaceuticals), Approved November, 2004
For the treatment of advanced refractory metastatic non-small cell lung cancer

Xalkori (crizotinib) (by Pfizer), Approved August of 2011
For the treatment of ALK+ non-small cell lung cancer

Zykadia (ceritinib) (by Novartis), Approved April 2014
For the treatment of ALK+ metastatic non-small cell lung cancer

Lupus

Benlysta (belimumab) (by Human Genome Sciences), Approved March 2011
For the treatment of systemic lupus erythematosus

Lymphocytic Leukemia, Acute

Arranon (nelarabine) (by GlaxoSmithKline), Approved October 2005
For the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma

Clolar (clofarabine) (by Genzyme), Approved December, 2004
For the treatment of acute lymphoblastic leukemia in pediatric patients

Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection) (by Orphan Medical), Approved October 1996
Treatment of meningeal leukemia or lymphocytic lymphoma

Erwinaze (asparaginase Erwinia chrysanthemi) (by Eusa Pharma), Approved November of 2011
For the treatment of acute lymphoblastic leukemia

Iclusig (ponatinib) (by Ariad Pharmaceuticals), Approved December 2012
For the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia

Marqibo (vinCRIStine sulfate LIPOSOME injection) (by Talon Therapeutics), Approved August 2012
For the treatment of Ph- acute lymphoblastic leukemia

Lymphoma

Adcetris (brentuximab vedotin) (by Seattle Genetics), Approved August 2011
For the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma

Opdivo (nivolumab) (by Bristol-Myers Squibb), Approved May 2016
For the treatment of classical Hodgkin lymphoma

Revlimid (lenalidomide) (by Celgene), Approved December 2005
For the treatment of low- and intermediate-1-risk myelodysplastic syndromes

Revlimid (lenalidomide) (by Celgene), Approved June 2013
For the treatment of mantle cell lymphoma

Zydelig (idelalisib) (by Gilead), Approved July 2014
For the treatment of relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma

Lymphoma, B-Cell

Yescarta (axicabtagene ciloleucel) (by Kite Pharmaceuticals), Approved October 2017
For the treatment of relapsed or refractory large B-cell lymphomas

Zydelig (idelalisib) (by Gilead), Approved July 2014
For the treatment of relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma

Lymphoproliferative disorders

Sylvant (siltuximab) (by Janssen Biotech), Approved April 2014
For the treatment of multicentric Castleman’s disease

Lysosomal Acid Lipase Deficiency (LAL)

Kanuma (sebelipase alfa) (by Alexion), Approved December 2015
For the treatment of Lysosomal Acid Lipase (LAL) deficiency